GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Tax Provision

Kyverna Therapeutics (Kyverna Therapeutics) Tax Provision : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Tax Provision?

Kyverna Therapeutics's tax provision for the three months ended in Mar. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Kyverna Therapeutics Tax Provision Historical Data

The historical data trend for Kyverna Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Tax Provision Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Tax Provision
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Tax Provision Get a 7-Day Free Trial - - - - -

Kyverna Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines